Adalta Ltd. · ASX:1AD
Adalta — Shareholder Meeting (November 2019)
22 slides from Adalta's shareholder meeting presentation, Nov 26, 2019
Slide 1: CEO report – Annual General Meeting
For personal use only CEO report Annual General Meeting 26 November 2019 Tim Oldham, CEO and Managing Director AdAlta Limited (ASX:1AD)
Slide 2: Disclaimer
Disclaimer For personal use only Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This presentation is not an offer or in
Slide 3: AdAlta overview
AdAlta overview For personal use only AdAlta Limited (ASX:1AD) is an Australian listed drug discovery and development company generating a promising new class of protein therapeutics, known as i-bodies, for treating a wide range of human diseases. 3
Slide 4: Introducing new CEO, Tim Oldham PhD
Introducing new CEO, Tim Oldham PhD For personal use only Commenced 14 October 2019 20 years’ executive leadership experience in Australia, Europe and Asia Senior pharma and biotech roles in strategic planning, business development (licensing, M&A), commercial and manufacturing operations and allian
Slide 5: AdAlta (1AD) investment summary
AdAlta (1AD) investment summary For personal use only i-body platform for generating multiple products – Novel structure provides new way to access important biological targets that can be difficult to access with conventional approaches Lead internal program, AD-214, due to commence human Phase 1 c
Slide 6: AdAlta business model and strategy to create value
AdAlta business model and strategy to create value For personal use only 1. In-house Licence to pharma pipeline of drug Revenues: major upfronts + candidates milestones & royalties AD-214 Invest up to key value inflection point i-body i-body drugs technology Long loop that enables and diagnostics pl
Slide 7: AdAlta pipeline
AdAlta pipeline IND Product/ Class of Manufact- For personal use only Partner Discovery Preclinical enabling Phase I Indication Target Target uring studies AD-214: Idiopathic CXCR4 GPCR Pulmonary Fibrosis AD-214: Other CXCR4 GPCR i-body discovery engine fibrotic indications Novel Not disclosed MCP-1
Slide 8: AD-214 has broad application in treating fibrosis
AD-214 has broad application in treating fibrosis For personal use only AdAlta data in animal models and human tissue studies suggests that AD-214 can improve fibrosis and inflammation across a range of fibrotic diseases LUNG: Idiopathic Pulmonary Fibrosis Lung Eye Liver EYE: Wet-Age Related Macular
Slide 9: Market opportunity for IPF
Market opportunity for IPF For personal use only Idiopathic Pulmonary Fibrosis (IPF) is an irreversible, unpredictable and incurable disease THE STATISTICS People living with IPF 300,000 People die from IPF every year 40,000 Median length of survival after IPF diagnosis 3.8 years 9
Slide 10: AdAlta’s place in the IPF treatment landscape
AdAlta’s place in the IPF treatment landscape For personal use only FDA approvals of pirfenidone and nintedanib in 2014 has led to greater confidence in the development of drugs for IPF – Neither are optimal therapies - the disease process is slowed, not reversed A number of products in development
Slide 11: AD-214 novel treatment for fibrosis – lung
AD-214 novel treatment for fibrosis – lung For personal use only AdAlta’s lead i-body has demonstrated in vivo activity (reduced collagen content, reduced inflammatory cell infiltration, improved tissue architecture) in a Bleomycin- induced mouse model of lung fibrosis Normal IPF lung tissue IPF lun
Slide 12: AD-214 safe in 4-week toxicology study
AD-214 safe in 4-week toxicology study For personal use only RECENT DATA 3 non-human primate studies completed Most recent: a Good Laboratory Practice (GLP) study to evaluate safety and toxicology prior to initial human studies – 10mg/kg, 30mg/kg and 100mg/kg multiple doses over four weeks plus reco
Slide 13: AD-214 development: key milestones
AD-214 development: key milestones For personal use only 2019 2020 Q3 Q4 Q1 Q2 Q3 Q4 Next steps • Manufacture drug product (vialling) and placebo Toxicology studies • Finalise engagement of clinical trial partners • Finalise Phase 1 study protocol and prepare ethics committee submission Clinical stu
Slide 14: GE Healthcare licensing deal – i-body platform
GE Healthcare licensing deal – i-body platform For personal use only Overview: Agreement with global medical technology and diagnostics firm, GE Healthcare AdAlta will screen its novel i-body library on a number of targets in order to identify i-bodies that GE can use as imaging agents, starting wit
Slide 15: Market benchmarks
Market benchmarks For personal use only Fibrosis Nov-19 acquired by Roche $390m + $1b – Phase II lead AD-214 Sep-15 acquired by Roche $105m + $475m milestones Jul-19 license by Boehringer Ingelheim €45m + €1.1b Aug-15 BMS option to buy phase I phase I $150m + $1.25b milestones Micro- Feb-18 collabor
Slide 16: Significant 2019 achievements
Significant 2019 achievements AD-214 For personal use only ✓ Successfully completed AD-214 cell-line and manufacturing process development; completed manufacturing of clinical AD-214 bulk drug substance ✓ Completed Phase I-enabling non-human primate toxicity (safety) studies (pharmacology data pendi
Slide 17: Financial position
Financial position Key financial details Share price performance (last 12 months) For personal use only ASX code 1AD Share price (25 November 2019) AUD$0.12 Market capitalisation AUD$22.18m Ordinary Shares 164,302,007 Listed Options 23,348,803 Unlisted Options 2,605,007 Current cash (30 September 20
Slide 18: Financial results
Financial results AUD million For personal use only Financial year cash flows Quarterly cash flows Net inflows* Cash FY18 FY19 10 Net outflows** (AUD million) (AUD million) Cash at end of quarter 8 Operating inflows 1.86 2.11 6 4 Operating outflows 5.79 7.93 2 Financing cash 0 0.01 9.24 flows (2) St
Slide 19: First month reflections
First month reflections Current CEO priorities For personal use only 1. Commence AD-214 clinical program 2. Deliver GE contract 3. Develop growth/expansion strategy AD-214 Platform Strategy • Busy but achievable plan to • Demonstrated ability to bind • Clear, confirmed opportunity reach clinic Q1 20
Slide 20: FY20 news flow
FY20 news flow New milestones For personal use only H2 2019 Partnership announcement – GE partnership September 2019 Publication of key i-body data in well recognised, peer reviewed scientific journal, mAbs 4-week NHP toxicology study – completed October 2019 (plus GMP production of AD214 bulk
Slide 21: AdAlta Limited (ASX:1AD) Summary
AdAlta Limited (ASX:1AD) Summary Platform technology for multiple pipeline products and partnerships For personal use only Lead asset AD-214 – Has significant pre-clinical validation demonstrating broad anti-fibrotic and anti-inflammatory effects as well as safety. – Initial focus on treating Idiopa
Slide 22: Contact us
For personal use only Contact us: Dr Tim Oldham, CEO & Managing Director [email protected] | +61 403 446 665 www.adalta.com.au 22